权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of A Multi-Modality System for Onco-Imaging

肿瘤成像多模态系统的开发

基本信息

批准号：
7316114
负责人：
GULTEKIN GULSEN
金额：
$ 22.46万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-08-01 至 2008-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7316114
关键词：
Academia Accounting Adenocarcinoma Algorithms Animals Anxiety Area Benign Biopsy Blood Blood Vessels Carcinogens Cicatrix Clinical Clinical Trials Collaborations Compatible Contrast Media Data Detection Development Devices Diagnostic Specificity Differential Diagnosis Diffusion Equation Ethylnitrosourea Evaluation Frequencies Functional Imaging Future Goals Hemoglobin Human Hybrids Image Imaging technology Industry Internal Breast Prosthesis Ions Kidney Kinetics Lead Lesion Literature Magnetic Resonance Imaging Malignant - descriptor Malignant Neoplasms Mammary Ultrasonography Maps Measures Methods Modality Modeling Modification Molecular Molecular Probes Molecular Weight Mono-S Nature Numbers Optical Tomography Optics Other Imaging Modalities Outcome Oxygen Patients Performance Permeability Phase Polymers Preparation Property Proteins Protocols documentation Purpose Rattus Reporting Research Resolution Risk Role Scheme Screening procedure Sensitivity and Specificity Site Specificity Staging System Techniques Technology Testing Time Tissues Toxic effect Translational Research Universities Validation Woman absorption albumin-(gadolinium-DTPA)angiogenesis base bioimaging breast lesion cancer diagnosis clinical application concept data acquisition design detector diagnostic accuracy diffuse optical tomography extracellular improved in vivo interstitial malignant breast neoplasm member novel optical imaging performance tests phantom model prototype reconstruction research study size subcutaneous technology development tissue oxygenation tool tumor uptake validation studies

项目摘要

DESCRIPTION (provided by applicant): Recently, the optical imaging field has been rapidly expanding in scope through the use of new exogenous molecular probes. We have already developed a multi-frequency & multi- spectral optical tomography animal imaging system and integrated to an MRI system. In this application, we will expand our hybrid system to measure dynamic information from exogenous probes. This system would measure the enhancement kinetics of the bi-functional MR/NIR or mono-functional NIR contrast agents in addition to the endogenous contrast due to hemoglobin contents and scattering properties. There are two main phases of the proposal. The first and the foremost phase is the technology development, which can be classified into two sub aims: a) the development of a novel multi-modality dynamic imaging system and b) the development of polymer based bi-functional and mono-functional NIR agents. We believe that such a hybrid system will facilitate the development of new contrast agents for biomedical imaging and that the development of polymer based molecular agents will provide a potential new molecular platform for these new contrast agents. In the second phase of the proposal, we will try to utilize this novel hybrid system together with a small molecular MR and a medium size (~30-40 kDa) novel polymer based optical agent. We will compare the role of all kinetic parameters and intrinsic properties obtained by MR/Optical imaging system, individually or combined, in cancer diagnosis after completing all analysis steps. Thus, we will be able to test our hypothesis that "the parameters obtained by macromolecular optical agent together with total hemoglobin, oxygen saturation and tissue scattering parameters can achieve a higher specificity in differentiating between ENU induced malignant and benign tumors compared to MRI parameters measured by low molecular weight extracellular MRI agents". We believe our collaboration with GE Global Research Center for the development of the novel MR/NIR contrast agents will serve to close the gap between the academia and the industries further for biomedical imaging applications. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors. With appropriate modifications in design, the proposed MR/Optical technology has a great translational potential for future human clinical trials. This application is aimed at developing a hybrid MR/DOT system along with novel polymer based contrast agents. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors.

描述（由申请人提供）：最近，通过使用新的外源分子探针，光学成像领域的范围迅速扩大。我们已经开发了一种多频多谱段光学断层动物成像系统，并集成到MRI系统中。在这个应用中，我们将扩展我们的混合系统来测量来自外源探针的动态信息。除了由于血红蛋白含量和散射性质引起的内源性对比之外，该系统还将测量双功能MR/NIR或单功能NIR对比剂的增强动力学。该提案有两个主要阶段。第一个也是最重要的阶段是技术开发，其可以分为两个子目标：a）开发新型多模态动态成像系统和B）开发基于聚合物的双功能和单功能近红外试剂。我们相信，这样的混合系统将促进新的造影剂的生物医学成像的发展和基于聚合物的分子试剂的发展将提供一个潜在的新的分子平台，这些新的造影剂。在该提案的第二阶段，我们将尝试利用这种新的混合系统与小分子MR和中等大小（~30-40 kDa）的新型聚合物为基础的光学试剂。在完成所有分析步骤后，我们将比较由MR/光学成像系统获得的所有动力学参数和固有特性单独或组合在癌症诊断中的作用。因此，我们将能够检验我们的假设，即“与通过低分子量细胞外MRI试剂测量的MRI参数相比，通过大分子光学试剂获得的参数与总血红蛋白、氧饱和度和组织散射参数一起可以在区分ENU诱导的恶性和良性肿瘤方面实现更高的特异性”。我们相信，我们与GE全球研究中心合作开发新型MR/NIR造影剂将有助于缩小学术界和工业界之间的差距，进一步推动生物医学成像应用。如果成功，我们的努力成果将提供一种复杂的工具，可以在肿瘤的检测和表征中提供高灵敏度和高特异性。通过适当的设计修改，所提出的MR/光学技术在未来的人体临床试验中具有巨大的转化潜力。本申请旨在开发一种混合MR/DOT系统，沿着新型聚合物造影剂。如果成功，我们的努力成果将提供一种复杂的工具，可以在肿瘤的检测和表征中提供高灵敏度和高特异性。